EOLS Insider Trading

Insider Ownership Percentage: 6.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $3,359,057.01

Evolus Insider Trading History Chart

This chart shows the insider buying and selling history at Evolus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Evolus Share Price & Price History

Current Price: $10.79
Price Change: Price Increase of +0.68 (6.73%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for EOLS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$10.79Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for Evolus (NASDAQ:EOLS)

90.69% of Evolus stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at EOLS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$3.20Mbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
Evolus logo
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Read More on Evolus

Today's Range

Now: $10.79
Low: $10.33
High: $10.97

50 Day Range

MA: $12.68
Low: $9.36
High: $15.04

52 Week Range

Now: $10.79
Low: $8.67
High: $17.82

Volume

1,051,617 shs

Average Volume

658,837 shs

Market Capitalization

$686.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Who are the company insiders with the largest holdings of Evolus?

Evolus' top insider investors include:
  1. Medytox Inc (Major Shareholder)
  2. David Moatazedi (Insider)
  3. Rui Avelar (Insider)
  4. Vikram Malik (Director)
  5. Sandra Beaver (CFO)
  6. Tomoko Yamagishi-Dressler (CMO)
  7. David N Gill (Director)
  8. Karah Herdman Parschauer (Director)
Learn More about top insider investors at Evolus.

Who are the major institutional investors of Evolus?

Evolus' top institutional shareholders include:
  1. Assenagon Asset Management S.A. — 1.12%
  2. Rhumbline Advisers — 0.13%
  3. GAMMA Investing LLC — 0.03%
Learn More about top institutional investors of Evolus stock.

Which major investors are buying Evolus stock?

Within the previous quarter, EOLS stock was acquired by institutional investors including:
  1. Assenagon Asset Management S.A.
  2. GAMMA Investing LLC
  3. Rhumbline Advisers